The prognostic value of neutrophil-to-lymphocyte ratio in cholangiocarcinoma: a systematic review and meta-analysis.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 07 2022
25 07 2022
Historique:
received:
21
02
2022
accepted:
14
07
2022
entrez:
25
7
2022
pubmed:
26
7
2022
medline:
28
7
2022
Statut:
epublish
Résumé
The neutrophil-to-lymphocyte ratio (NLR) is used as biomarker in malignant diseases showing significant association with poor oncological outcomes. The main research question of the present study was whether NLR has also prognostic value in cholangiocarcinoma patients (CCA). A systematic review was carried out to identify studies related to NLR and clinical outcomes in CCA evaluating the literature from 01/2000 to 09/2021. A random-effects model, pooled hazard ratios (HR) and 95% confidence interval (CI) were used to investigate the statistical association between NLR and overall survival (OS) as well as disease-free survival (DFS). Subgroup analyses, evaluation of sensitivity and risk of bias were further carried out. 32 studies comprising 8572 patients were eligible for this systematic review and meta-analysis. The pooled outcomes revealed that high NLR prior to treatment is prognostic for poor OS (HR 1.28, 95% CI 1.18-1.38, p < 0.01) and DFS (HR 1.39, 95% CI 1.17-1.66, p < 0.01) with meaningful HR values. Subgroup analysis revealed that this association is not significantly affected by the treatment modality (surgical vs. non-surgical), NLR cut-off values, age and sample size of the included studies. Given the likelihood of NLR to be prognostic for reduced OS and DFS, pre-treatment NLR might serve as a useful biomarker for poor prognosis in patients with CCA and therefore facilitate clinical management.
Identifiants
pubmed: 35879385
doi: 10.1038/s41598-022-16727-w
pii: 10.1038/s41598-022-16727-w
pmc: PMC9314341
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
12691Informations de copyright
© 2022. The Author(s).
Références
Anticancer Res. 2017 Jun;37(6):3229-3237
pubmed: 28551669
BMC Cancer. 2020 Sep 23;20(1):907
pubmed: 32967632
Liver Cancer. 2021 Jun;10(3):260-274
pubmed: 34239812
Gastroenterol Res Pract. 2021 Mar 26;2021:6616062
pubmed: 33833794
World J Gastroenterol. 2015 Mar 7;21(9):2807-15
pubmed: 25759553
J Gastroenterol. 2016 Feb;51(2):153-61
pubmed: 26187429
Eur J Gastroenterol Hepatol. 2014 Sep;26(9):1047-54
pubmed: 25051217
Oncol Lett. 2019 Jan;17(1):165-174
pubmed: 30655752
Cancer Manag Res. 2019 Oct 30;11:9107-9119
pubmed: 31802940
HPB (Oxford). 2016 Nov;18(11):950-957
pubmed: 27683047
Sci Rep. 2016 Feb 25;6:22089
pubmed: 26912340
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
Clin Colorectal Cancer. 2019 Jun;18(2):81-90
pubmed: 30905548
Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80
pubmed: 27095655
Oncotarget. 2016 Aug 9;7(32):50963-50971
pubmed: 26918355
Front Immunol. 2019 Jul 24;10:1713
pubmed: 31396225
Sci Rep. 2017 Feb 17;7:42954
pubmed: 28211504
Oncology. 2019;96(6):290-298
pubmed: 30909286
Ann Surg Oncol. 2017 May;24(5):1351-1357
pubmed: 28108828
BMC Surg. 2021 Mar 6;21(1):113
pubmed: 33676467
HPB (Oxford). 2020 Dec;22(12):1667-1674
pubmed: 32265108
Sci Rep. 2016 Oct 03;6:33789
pubmed: 27694951
Cancers (Basel). 2022 Jan 16;14(2):
pubmed: 35053599
Ann Surg Oncol. 2016 Feb;23(2):646-54
pubmed: 26416715
Eur J Surg Oncol. 2019 Aug;45(8):1468-1478
pubmed: 31053477
J Hepatobiliary Pancreat Sci. 2016 Oct;23(10):636-642
pubmed: 27474781
J Cancer. 2019 Jan 1;10(2):494-503
pubmed: 30719145
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Int J Cancer. 2014 May 15;134(10):2403-13
pubmed: 24122750
Cancer Med. 2019 Aug;8(9):4135-4148
pubmed: 31197958
Trials. 2007 Jun 07;8:16
pubmed: 17555582
Cancer Med. 2019 Oct;8(13):5916-5929
pubmed: 31429524
J Surg Oncol. 2008 May 1;97(6):513-8
pubmed: 18335453
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
Cancer. 1970 Jan;25(1):135-40
pubmed: 5410303
Tumour Biol. 2015 Jul;36(7):5283-9
pubmed: 25672606
Cancers (Basel). 2021 Jul 21;13(15):
pubmed: 34359564
Ann Surg Oncol. 2014 Nov;21(12):3938-46
pubmed: 24866438
Surgery. 2018 Sep;164(3):411-418
pubmed: 29903509
Nature. 2019 Feb;566(7745):553-557
pubmed: 30728496
J Cancer Res Clin Oncol. 2019 Oct;145(10):2541-2546
pubmed: 31367835
Clinics (Sao Paulo). 2015 Jul;70(7):524-30
pubmed: 26222823
Medicine (Baltimore). 2020 Oct 23;99(43):e22827
pubmed: 33120809
Cancer Chemother Pharmacol. 2020 Feb;85(2):265-272
pubmed: 31907646
Surgery. 2017 Oct;162(4):752-765
pubmed: 28688518
Surg Today. 2020 Apr;50(4):379-388
pubmed: 31667580
Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30
pubmed: 23602134
J Gastrointest Surg. 2019 Mar;23(3):510-517
pubmed: 30076591
Eur J Cancer. 2011 Nov;47(17):2633-41
pubmed: 21724383
Nucl Med Commun. 2020 Jan;41(1):78-86
pubmed: 31800510
J Immunol. 1987 Nov 15;139(10):3406-15
pubmed: 3316383
Eur J Cancer. 2014 Jun;50(9):1581-9
pubmed: 24630393
Transpl Int. 2021 Aug;34(8):1468-1480
pubmed: 34157178
Pancreatology. 2013 Sep-Oct;13(5):534-8
pubmed: 24075520
Medicine (Baltimore). 2015 Apr;94(13):e574
pubmed: 25837750
Gastroenterology. 2013 Dec;145(6):1215-29
pubmed: 24140396
Cell Physiol Biochem. 2017;44(3):967-981
pubmed: 29179180
J Clin Invest. 2010 Apr;120(4):1151-64
pubmed: 20237412
World J Surg Oncol. 2020 Oct 23;18(1):272
pubmed: 33097053
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Med Oncol. 2014 Jan;31(1):787
pubmed: 24310810
Sci Rep. 2020 Oct 15;10(1):17495
pubmed: 33060826
Cancer Treat Rev. 2013 Aug;39(5):534-40
pubmed: 22995477
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
Oncotarget. 2016 Nov 22;7(47):76604-76612
pubmed: 27780932
J Gastrointest Surg. 2013 May;17(5):913-24
pubmed: 23319395
J Clin Med. 2021 Jun 30;10(13):
pubmed: 34209368
Cancer Immunol Immunother. 2016 Feb;65(2):141-50
pubmed: 26728479
Br J Cancer. 2017 May 23;116(11):1444-1450
pubmed: 28427085
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404